Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Heart Pump Device Market Size and Upcoming Technological Innovations Will Boom in 2022-2028 | Analyzed by Size Share, Trends, Key Players & Future Growth Outlook

In This Article:

Leading market players are Medtronic, Abbott, Boston Scientific Corporation, Terumo Medical Corporation, W. L. Gore & Associates, and others

Luton, Bedfordshire, United Kingdom, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Heart Pump Device Market.

The Global Heart Pump Device Market is expected to grow at more than 21% CAGR from 2020 to 2028. It is expected to reach above USD 7 billion by 2028 from a little above USD 1.6 billion in 2020.

Increasing prevalence of cardiovascular infections and rising geriatric population are the major market drivers for the heart pump devices market. Different types of heart pumps are available to support your cardiovascular system, depending on your cardiovascular disease. They are precisely implanted and intended to provide short- or long-term cardiac support to people with weak hearts or unpredictable blood flow. Heart pump devices have long served as a promising treatment option to support mechanical circulation.

Heart failure is a condition in which the heart cannot pump enough blood to meet the body's needs. This condition can be caused by a variety of factors, including coronary artery disease, including previous myocardial infarction (heart attack), high blood pressure, atrial fibrillation, and heart valve infections.

The development of this market is driven by growing speculation, wealth and accolades for heart failure treatment research. increased prevalence of cardiovascular infections; longer waiting times for heart transplantation; Ideal return on investment for heart pump devices.

Request a PDF sample of this premium research:  https://exactitudeconsultancy.com/reports/1173/heart-pump-device-market/#request-a-sample    

Industry Insights:

Medtronic: FDA slaps Class I label on Medtronic's latest heart pump recall

Overview: Even a year after being laid to rest, the troubled Heart Ware Ventricular Assist Device, or HVAD, system is still causing problems for Medtronic.

Boston Scientific Corporation- Boston Scientific Announces FDA Approval of Innovative New Defibrillators And Heart Failure Devices

Overview: Boston Scientific Corporation (NYSE: BSX) has received FDA approval for its latest generation of defibrillators and heart failure devices designed to advance patient care. The newly approved devices include the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds.